These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36758709)

  • 1. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
    Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
    Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
    Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing of fetal growth and elevated maternal serum sFLT1:PlGF are associated with early term spontaneous labor.
    Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
    Am J Obstet Gynecol; 2021 Nov; 225(5):520.e1-520.e10. PubMed ID: 33901486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble fms-like tyrosine kinase-1/placental growth factor ratio at 36 weeks' gestation: association with spontaneous onset of labor and intrapartum fetal compromise in low-risk pregnancies.
    Farina A; Cavoretto PI; Syngelaki A; Adjahou S; Nicolaides KH
    Am J Obstet Gynecol; 2024 Aug; ():. PubMed ID: 39181498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing.
    Espinoza J; Calsavara VF; Kilpatrick S; Rana S; Costantine MM; Boggess K; Wylie BJ; Moore Simas TA; Louis JM; Gaw SL; Murtha A; Wiegand S; Gollin Y; Singh D; Silver RM; Durie DE; Panda B; Norwitz ER; Burd I; Plunkett B; Scott RK; Lemoine E; Thadhani R; Karumanchi SA
    Am J Obstet Gynecol; 2024 Sep; 231(3):363.e1-363.e11. PubMed ID: 38825028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of imminent preeclampsia at 35-37 weeks gestation.
    Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.
    Chaemsaithong P; Gil MM; Chaiyasit N; Cuenca-Gomez D; Plasencia W; Rolle V; Poon LC
    Am J Obstet Gynecol; 2023 Sep; 229(3):222-247. PubMed ID: 36990308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients.
    Parry S; Carper BA; Grobman WA; Wapner RJ; Chung JH; Haas DM; Mercer B; Silver RM; Simhan HN; Saade GR; Reddy UM; Parker CB;
    Am J Obstet Gynecol; 2022 Sep; 227(3):497.e1-497.e13. PubMed ID: 35487327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal vascular indices at 36 weeks' gestation in the prediction of preeclampsia.
    Mansukhani T; Wright A; Arechvo A; Lamanna B; Menezes M; Nicolaides KH; Charakida M
    Am J Obstet Gynecol; 2024 Apr; 230(4):448.e1-448.e15. PubMed ID: 37778678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study.
    Boutin A; Guerby P; Gasse C; Tapp S; Bujold E
    Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The additive role of angiogenic markers for women with confirmed preeclampsia.
    Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
    Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study.
    Andersen LB; Dechend R; Karumanchi SA; Nielsen J; Joergensen JS; Jensen TK; Christesen HT
    Am J Obstet Gynecol; 2016 Nov; 215(5):594.e1-594.e11. PubMed ID: 27287686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
    Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL
    Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
    Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
    Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia: a secondary analysis of the INSPIRE trial.
    Palma Dos Reis CR; O'Sullivan J; Ohuma EO; James T; Papageorghiou AT; Vatish M; Cerdeira AS
    Am J Obstet Gynecol; 2024 Jun; ():. PubMed ID: 38897339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
    Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
    Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The implications of the Fetal Medicine Foundation 35- to 36-week preeclampsia prediction competing-risk model on timing of birth.
    von Dadelszen P; Syngelaki A; Wright A; Akolekar R; Magee LA; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2023 Apr; 228(4):457.e1-457.e7. PubMed ID: 36206987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.